EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY-NC-ND 4.0

A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy

Filip K Knop iD, Shweta Urva iD, Mallikarjuna Rettiganti, Charles T Benson, William C Roell, Kieren J Mather iD, Axel Haupt iD, Edward John Pratt iD

Diabetes, Obesity and Metabolism · 2024-11 · 26 (11) · 5474-5478

DOI: 10.1111/dom.15875 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 27.08.2024. Verfasst von Filip K Knop und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsHumansMaleFemaleMiddle AgedReceptors, Gastrointestinal HormoneGastric Inhibitory Polypeptide

Stichwörter der Autor:innen

GIPGLP‐1antidiabetic drugantiobesity drugclinical trialincretin therapy

Substanzen

Hypoglycemic AgentsReceptors, Gastrointestinal Hormonegastric inhibitory polypeptide receptorGastric Inhibitory PolypeptideGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Steno Diabetes Center Copenhagen, Herlev, Denmark.
  • Eli Lilly and Company, Indianapolis, Indiana, USA.

ORCID-Profile: Filip K Knop, Shweta Urva, Kieren J Mather, Axel Haupt, Edward John Pratt

Förderung

  • Eli Lilly and Company

Zitieren

APA

Knop, F. K., Urva, S., Rettiganti, M., Benson, C. T., Roell, W. C., Mather, K. J., Haupt, A., & Pratt, E. J. (2024). A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy. Diabetes, Obesity and Metabolism, 26(11), 5474-5478. https://doi.org/10.1111/dom.15875

Vancouver

Knop FK, Urva S, Rettiganti M, Benson CT, Roell WC, Mather KJ, et al. A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy. Diabetes, Obesity and Metabolism. 2024;26(11):5474-5478. doi:10.1111/dom.15875

BibTeX
@article{Knop2024,
  author = {Knop, Filip K and Urva, Shweta and Rettiganti, Mallikarjuna and Benson, Charles T and Roell, William C and Mather, Kieren J and Haupt, Axel and Pratt, Edward John},
  title = {A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  volume = {26},
  number = {11},
  pages = {5474--5478},
  doi = {10.1111/dom.15875}
}
Kostenlos starten →